Calcified Tissue International

, Volume 105, Issue 4, pp 412–422 | Cite as

Vitamin D Status in Paget Disease of Bone and Efficacy–Safety Profile of Cholecalciferol Treatment in Pagetic Patients with Hypovitaminosis D

  • Domenico RendinaEmail author
  • Gianpaolo De Filippo
  • Daniela Merlotti
  • Marco Di Stefano
  • Mariangela Succoio
  • Simona Maria Muggianu
  • Simone Bianciardi
  • Lanfranco D’Elia
  • Eleonora Coppo
  • Raffaella Faraonio
  • Ranuccio Nuti
  • Pasquale Strazzullo
  • Luigi Gennari
Original Research


Adequate vitamin D status is essential for skeletal health. Paget’s disease of bone (PDB) is a common metabolic skeletal disorder, but data regarding the vitamin D status in PDB patients are lacking. We performed a case–control study to estimate vitamin D status in 708 PDB patients and in 1803 healthy controls from Italy and an observational prospective study to evaluate the efficacy–safety profile of oral cholecalciferol treatment [400.000 International Units (UI) of cholecalciferol administered in cycles of 8 weeks until 25OHD levels reaches 70 nmol/L as primary therapy and 50.000 UI of cholecalciferol administered every 2 weeks for 52 weeks for the maintenance therapy] in 82 PDB patients with hypovitaminosis D, i.e., 25OHD < 50 nmol/L. The main outcome measures for the prospective study were 25OHD levels, metabolic risk factors (RF) for nephrolithiasis, bone pain score (BPS), and pain medication score (PMS). Over half of PDB patients had hypovitaminosis D. Among PDB patients treated with cholecalciferol, 76 patients reached 25OHD levels ≥ 70 nmol/L after the first cycle of primary therapy and the remaining six patients after a second cycle. The maintenance therapy guaranteed 25OHD levels ≥ 70 nmol/L during the entire follow-up. The increase in 25OHD levels reduced PTH, BPS, and PMS levels, without changes in RF for nephrolithiasis. We can conclude that (i) hypovitaminosis D is frequent in PDB patients, (ii) cholecalciferol significantly increased 25OHD levels in PDB patients, and (iii) the correction of hypovitaminosis D improves the quality of life of PDB patients without inducing significant changes in RF for nephrolithiasis.


Paget’s disease of bone Cholecalciferol 25OHD Hypovitaminosis D Efficacy Safety 


Author Contributions

DR designed the study and prepared the first draft of the paper. He is guarantor. GDF, DM, MDS, MS, SMM, SB, EC, RF, RN, PS, and LG contributed to the experimental work. LD’E was responsible for statistical analysis of the data.


This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Compliance with Ethical Standards

Conflict of interest

Domenico Rendina, Gianpaolo De Filippo, Daniela Merlotti, Marco Di Stefano, Mariangela Succoio, Simona Maria Muggianu, Simone Bianciardi, Lanfranco D’Elia, Eleonora Coppo, Raffaella Faraonio, Ranuccio Nuti, Pasquale Strazzullo, and Luigi Gennari declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Ethical Approval

All procedures performed in this study, which involves human participants, were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Human and Animal Rights and Informed Consent

Written informed consent has been obtained from each patient or subject after full explanation of the purpose and nature of all used procedures. The study protocol was approved by the Federico II University Ethical Committee.


  1. 1.
    Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281CrossRefGoogle Scholar
  2. 2.
    Francis RM, Aspray TJ, Bowring CE, Fraser WD, Gittoes NJ, Javaid MK, Macdonald HM, Patel S, Selby PL, Tanna N (2015) National osteoporosis society practical clinical guideline on vitamin D and bone health. Maturitas 80:119–121CrossRefGoogle Scholar
  3. 3.
    Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930CrossRefGoogle Scholar
  4. 4.
    Ralston SH (2013) Clinical practice. Paget’s disease of bone. N Engl J Med 368:644–650CrossRefGoogle Scholar
  5. 5.
    Gennari L, Rendina D, Falchetti A, Merlotti D. Paget’s disease of bone. Calcif Tissue Int in pressGoogle Scholar
  6. 6.
    Seitz S, Priemel M, von Domarus C, Beil FT, Barvencik F, Amling M, Rueger JM (2008) The second most common bone disease: a review on Paget’s disease of bone. Eur J Trauma Emerg Surg 34:549–553CrossRefGoogle Scholar
  7. 7.
    Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Ralston S (2013) Epidemiology of Paget’s disease of bone: a systematic review and meta-analysis of secular changes. Bone 55:347–352CrossRefGoogle Scholar
  8. 8.
    van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 17:465–471CrossRefGoogle Scholar
  9. 9.
    Rendina D, Gennari L, De Filippo G, Merlotti D, de Campora E, Fazioli F, Scarano G, Nuti R, Strazzullo P, Mossetti G (2006) Evidence for increased clinical severity of familial and sporadic Paget’s disease of bone in Campania, southern Italy. J Bone Miner Res 21:1828–1835CrossRefGoogle Scholar
  10. 10.
    Siris ES, Lyles KW, Singer FR, Meunier PJ (2006) Medical management of Paget’s disease of bone: indications for treatment and review of current therapies. J Bone Miner Res 21:P94–P98CrossRefGoogle Scholar
  11. 11.
    Gennari L, Gianfrancesco F, Di Stefano M, Rendina D, Merlotti D, Esposito T, Gallone S, Fusco P, Rainero I, Fenoglio P, Mancini M, Martini G, Bergui S, De Filippo G, Isaia G, Strazzullo P, Nuti R, Mossetti G (2010) SQSTM1 gene analysis and gene-environment interaction in Paget’s disease of bone. J Bone Miner Res 25:1375–1384CrossRefGoogle Scholar
  12. 12.
    Fillée C, Keller T, Mourad M, Brinkmann T, Ketelslegers JM (2012) Impact of vitamin D-related serum PTH reference values on the diagnosis of mild primary hyperparathyroidism, using bivariate calcium/PTH reference regions. Clin Endocrinol 76:785–789CrossRefGoogle Scholar
  13. 13.
    Rendina D, Gianfrancesco F, De Filippo G, Merlotti D, Esposito T, Mingione A, Nuti R, Strazzullo P, Mossetti G, Gennari L (2010) FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur J Endocrinol 163:165–172CrossRefGoogle Scholar
  14. 14.
    Cooper DS, Biondi B (2012) Subclinical thyroid disease. Lancet 379:1142–1154CrossRefGoogle Scholar
  15. 15.
    Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, Buchholz N, Bushinsky D, Curhan GC, Ferraro PM, Fuster D, Goldfarb DS, Heilberg IP, Hess B, Lieske J, Marangella M, Milliner D, Preminger GM, Reis Santos JM, Sakhaee K, Sarica K, Siener R, Strazzullo P, Williams JC; Consensus Conference Group (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 29:715–734CrossRefGoogle Scholar
  16. 16.
    Kaye AD, Cornett EM, Hart B, Patil S, Pham A, Spalitta M, Mancuso KF (2018) Novel pharmacological nonopioid therapies in chronic pain. Curr Pain Headache Rep 22:31CrossRefGoogle Scholar
  17. 17.
    Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases. Final results of the study by the radiation therapy oncology group. Cancer 50:893–899CrossRefGoogle Scholar
  18. 18.
    Rendina D, De Filippo G, Postiglione L, Covelli B, Ricciardone M, Guillaume S, Di Spigna G, Selleri C, Merlotti D, Bianciardi S, Materozzi M, Muscariello R, De Pascale F, DʼElia L, Nuti R, Strazzullo P, Gennari L (2018) Interleukin-6 trans-signaling and pathological low back pain in patients with Paget disease of bone. Pain 159:1664–1673CrossRefGoogle Scholar
  19. 19.
    Tiselius HG (2013) A proposed method for approximate estimates of the ion-activity products of calcium oxalate and calcium phosphate in spot-urine samples or in urine samples collected during less well defined periods of time. Urolithiasis 41:105–109CrossRefGoogle Scholar
  20. 20.
    Coe FL, Evan A, Worcester E (2005) Kidney stone disease. J Clin Invest 115:2598–2608CrossRefGoogle Scholar
  21. 21.
    Rubenstein L, Robbins A, Josephson K, Schulman B, Osterweil D (1990) The value of assessing falls in an elderly population: a randomised clinical trial. Ann Intern Med 113:308–316CrossRefGoogle Scholar
  22. 22.
    Conley D, Schultz AA, Selvin R (1999) The challenge of predicting patients at risk for falling: development of the Conley Scale. Medsurg Nurs 8:348–354Google Scholar
  23. 23.
    Rendina D, Mossetti G, Viceconti R, Sorrentino M, Castaldo R, Manno G, Guadagno V, Strazzullo P, Nunziata V (2004) Association between vitamin D receptor gene polymorphisms and fasting idiopathic hypercalciuria in recurrent stone-forming patients. Urology 64:833–838CrossRefGoogle Scholar
  24. 24.
    Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, Dotta F, Nuti R (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97:1737–1744CrossRefGoogle Scholar
  25. 25.
    Thomas L (1997) Retrospective power analysis. Conserv Biol 11:276–280CrossRefGoogle Scholar
  26. 26.
    Battista C, Guarnieri V, Carnevale V, Baorda F, Pileri M, Garrubba M, Salcuni AS, Chiodini I, Minisola S, Romagnoli E, Eller-Vainicher C, Santini SA, Parisi S, Frusciante V, Fontana A, Copetti M, Hendy GN, Scillitani A, Cole DE (2017) Vitamin D status in primary hyperparathyroidism: effect of genetic background. Endocrine 55:266–272CrossRefGoogle Scholar
  27. 27.
    Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V (2004) Risedronate and pamidronate treatment in the clinical management of patients with severe Paget’s disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int 75:189–196CrossRefGoogle Scholar
  28. 28.
    Gennari L, Merlotti D, Mossetti G, Rendina D, De Paola V, Martini G, Nuti R (2009) The use of intravenous aminobisphosphonates for the treatment of Paget’s disease of bone. Mini Rev Med Chem 9:1052–1063CrossRefGoogle Scholar
  29. 29.
    Griz L, Bandeira F, Diniz ET, Cabral M, Freese E (2013) Prevalence of vitamin D deficiency is higher in patients with Paget’s disease of bone compared with age-matched controls. Arq Bras Endocrinol Metabol 57:509–512CrossRefGoogle Scholar
  30. 30.
    de Deuxchaisnes CN, Rombouts-Lindemans C, Huaux JP, Devogelaer JP, Withofs H, Meersseman F (1981) Relative vitamin D deficiency in Paget’s disease. Lancet 1:833–834CrossRefGoogle Scholar
  31. 31.
    Guillard-Cumming DF, Beard DJ, Douglas DL, Johnson SK, Lawson-Matthew PJ, Russell RG, Kanis JA (1985) Abnormal vitamin D metabolism in Paget’s disease of bone. Clin Endocrinol (Oxf) 22:559–566CrossRefGoogle Scholar
  32. 32.
    Foldes J, Shamir S, Kidroni G, Menczel J (1989) Vitamin D in Paget’s disease of bone. Clin Orthop Relat Res 243:275–279Google Scholar
  33. 33.
    Nunziata V, Giannattasio R, di Giovanni G, Lettera AM, Nunziata CA (1993) Vitamin D status in Paget’s bone disease. Effects of calcitonin therapy. Clin Orthop Relat Res 293:366–371Google Scholar
  34. 34.
    Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Manson JE, Mayne ST, Ross AC, Shapses SA, Taylor CL (2012) IOM committee members respond to endocrine society vitamin D guideline. J Clin Endocrinol Metab 97:1146–1152CrossRefGoogle Scholar
  35. 35.
    Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2012) Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 97:1153–1158CrossRefGoogle Scholar
  36. 36.
    Bettica P, Bevilacqua M, Vago T, Norbiato G (1999) High prevalence of hypovitaminosis D among free-living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening. Osteoporos Int 9:226–229CrossRefGoogle Scholar
  37. 37.
    Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S (2003) Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 14:577–582CrossRefGoogle Scholar
  38. 38.
    Lips P, Cashman KD, Lamberg-Allardt C, Bischoff-Ferrari HA, Obermayer-Pietsch BR, Bianchi M, Stepan J, El-Hajj Fuleihan G, Bouillon R. MANAGEMENT OF ENDOCRINE DISEASE: Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency; a position statement of the European Calcified Tissue Society. Eur J Endocrinol. in pressGoogle Scholar
  39. 39.
    Close GL, Leckey J, Patterson M, Bradley W, Owens DJ, Fraser WD, Morton JP (2013) The effects of vitamin D(3) supplementation on serum total 25[OH]D concentration and physical performance: a randomised dose-response study. Br J Sports Med 47:692–696CrossRefGoogle Scholar
  40. 40.
    Wagner D, Hanwell HE, Schnabl K, Yazdanpanah M, Kimball S, Fu L, Sidhom G, Rousseau D, Cole DE, Vieth R (2011) The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) response to vitamin D(3) supplementation. J Steroid Biochem Mol Biol 126:72–77CrossRefGoogle Scholar
  41. 41.
    Singer FR, Bone HG 3rd, Hosking DJ, Lyles KW, Murad MH, Reid IR, Siris ES; Endocrine Society (2014) Paget’s disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:4408–4422CrossRefGoogle Scholar
  42. 42.
    Mossetti G, Vuotto P, Rendina D, Numis FG, Viceconti R, Giordano F, Cioffi M, Scopacasa F, Nunziata V (2003) Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis. J Intern Med 253:194–200CrossRefGoogle Scholar
  43. 43.
    Rendina D, De Filippo G, Gianfrancesco F, Muscariello R, Schiano di Cola M, Strazzullo P, Esposito T (2017) Evidence for epistatic interaction between VDR and SLC13A2 genes in the pathogenesis of hypocitraturia in recurrent calcium oxalate stone formers. J Nephrol 30:411–418CrossRefGoogle Scholar
  44. 44.
    Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C (2014) Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 10:007470Google Scholar
  45. 45.
    Brandi ML, Falchetti A (2006) What is the relationship between Paget’s disease of bone and hyperparathyroidism? J Bone Miner Res 21:P69–P74CrossRefGoogle Scholar
  46. 46.
    Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303:1815–1822CrossRefGoogle Scholar
  47. 47.
    Sanders KM, Nicholson GC, Ebeling PR (2013) Is high dose vitamin D harmful? Calcif Tissue Int 92:191–206CrossRefGoogle Scholar
  48. 48.
    Mackenzie L, Byles J, D’Este C (2006) Validation of self-reported fall events in intervention studies. Clin Rehabil 20:331–339CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Domenico Rendina
    • 1
    Email author
  • Gianpaolo De Filippo
    • 2
  • Daniela Merlotti
    • 3
  • Marco Di Stefano
    • 4
  • Mariangela Succoio
    • 5
  • Simona Maria Muggianu
    • 5
  • Simone Bianciardi
    • 3
  • Lanfranco D’Elia
    • 1
  • Eleonora Coppo
    • 4
  • Raffaella Faraonio
    • 5
  • Ranuccio Nuti
    • 3
  • Pasquale Strazzullo
    • 1
  • Luigi Gennari
    • 3
  1. 1.Department of Medicine and SurgeryFederico II UniversityNaplesItaly
  2. 2.Service de Médecine des AdolescentsAssistance Publique-Hôpitaux de Paris, Hôpital BicêtreLe Kremlin BicêtreFrance
  3. 3.Department of Medicine, Surgery and NeurosciencesUniversity of SienaSienaItaly
  4. 4.Department of Medical Science, Gerontology and Bone Metabolic DiseasesUniversity of TorinoTurinItaly
  5. 5.Department of Molecular Medicine and Medical BiotechnologyUniversity of Naples Federico IINaplesItaly

Personalised recommendations